Autopsy report · NCT06454409
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cause of deathStaffing, sites or logistics
“resources”
Life of this trial
- Registered 11 months before it started.
- Suspended: paused, and may or may not restart.
- 20 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 1
- Sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Myelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
- Interventions
- Azacitidine; Biospecimen Collection; Bone Marrow Aspiration; Regorafenib; Venetoclax
- Participants
- 20 (planned, not actual)
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate
“Not enough resources” - Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy
“Failed resources.” - Chronic Pain, Couples, & Physical Activity
“Resources not available.” - Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
“No available resources.” - T1 Diabetes Hypoglycemia Prevention Pilot
“Insufficient Resources”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.